Metsera
Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs
Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding
Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism
Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends
Metsera Raises $275M in IPO to Advance GLP-1 Weight Loss Drug to Phase 3
Metsera, IPO, GLP-1 receptor agonist, MET-097i, obesity treatment, weight loss drug, clinical trials, biotech funding
Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing
Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease
Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data
Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides
Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera
Metsera, Amneal, Obesity Drugs, Strategic Collaboration, Manufacturing Partnership, Leadership Transition
Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss in 36 Days, Paving Way for Monthly Dosing
Metsera, GLP-1, obesity treatment, long-acting drug, weight loss, monthly dosing, MET-097, clinical trial results.
Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo
Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)